Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. ChemoCentryx (CCXI) downgraded to Neutral from Overweight at JPMorgan with analyst Anupam Rama saying he views the Phase 2 AURORA results for avacopan in hidradenitis suppurativa as "mixed." 2. First Solar (FSLR) downgraded to Neutral from Overweight at JPMorgan with analyst Paul Coster saying after rallying 67% year-to-date, the stock is now trading close to the price target and at "historically-elevated" multiples. 3. Exact Sciences (EXAS) downgraded to Neutral from Buy at UBS with analyst Dan Brennan saying the company's acquisition of Thrive is "strategically sound," but at current levels, the risk/reward on the stock is "more balanced." 4. C.H. Robinson (CHRW) downgraded to Equal Weight from Overweight at Stephens with analyst Jack Atkins saying he continues to view C.H. Robinson as a long-term winner as the third-party logistics industry consolidates, he prefers to move to the sidelines until there is greater visibility into the volume growth that he sees as necessary to drive revenue and profitability growth. 5. CAE (CAE) downgraded to Hold from Buy at Canaccord with analyst Doug Taylor citing valuation and a lack of visibility on growth reacceleration. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.